Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

357
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
357
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

409
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
409
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

442
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
442

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[Identification of the entosis stages in situ in lung cancer tissue and their changes after neoadjuvant chemotherapy].

Arkhiv patologii·2026
Same author

[Vascular dysfunction: Processes Caused by aging, approaches to restorative therapy and prevention (part 2).]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

[TRPS1 as a novel immunohistochemical marker in breast cancer diagnosis].

Arkhiv patologii·2026
Same author

[Vascular dysfunction: processes due to aging, approaches to restorative therapy and prevention (part 1).]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

From heterogeneity to hope: emerging markers in triple-negative breast cancer research.

Medical oncology (Northwood, London, England)·2025
Same author

[Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations].

Arkhiv patologii·2025

相关实验视频

Updated: Jun 23, 2025

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.0K

克森的抗聚合作用 克森的抗聚合作用

V V Udut1,2, D V Tsuran1, S A Naumov1

  • 1E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Bulletin of experimental biology and medicine
|June 18, 2024
PubMed
概括
此摘要是机器生成的。

气 (Xe) 显著降低了血小板聚合,无论是自发的还是由常见激动剂诱导的. 这一发现表明,在治疗与血小板有关的疾病方面,具有潜在的治疗应用.

关键词:
异;血小板;聚合;聚合诱导剂.

更多相关视频

Hyperpolarized Xenon for NMR and MRI Applications
16:20

Hyperpolarized Xenon for NMR and MRI Applications

Published on: September 6, 2012

19.5K
Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology
10:52

Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology

Published on: April 23, 2019

12.9K

相关实验视频

Last Updated: Jun 23, 2025

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.0K
Hyperpolarized Xenon for NMR and MRI Applications
16:20

Hyperpolarized Xenon for NMR and MRI Applications

Published on: September 6, 2012

19.5K
Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology
10:52

Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology

Published on: April 23, 2019

12.9K

科学领域:

  • 生物化学 生物化学
  • 药理学 药理学是指药理学的学科.
  • 血液学 血液学 血液学

背景情况:

  • 血小板聚合在血液静止和血栓形成中起着至关重要的作用.
  • 血小板功能障碍与各种心血管和出血疾病有关.
  • 持续寻找针对血小板活动的新型治疗剂.

研究的目的:

  • 为了研究 (Xe) 对血小板聚合的体外影响.
  • 为了确定对自发性和激动剂诱导的血小板聚合的影响.

主要方法:

  • 一个采用血小板丰富血的体外模型.
  • 使用原蛋白,ADP,瑞斯托和上腺素诱导血小板聚合.
  • 测量血小板聚合在存在的Xenon的毫米度.

主要成果:

  • 克森显著降低了由原诱导 (≈30%) 和ADP诱导 (≈25%) 的血小板聚合.
  • 也减少了瑞斯托诱导的 (≈12%) 和上腺素诱导的 (≈9%) 聚合.
  • 自发的血小板聚合被降低了两倍.

结论:

  • 克森在体外对血小板表现出强大的抗聚合作用.
  • 克森的机制可能涉及膜脂质相互作用和NMDA受体阻塞.
  • 这些发现强调了作为治疗血小板功能障碍的治疗剂的潜力.